SEARCH

SEARCH BY CITATION

REFERENCES

  • Barderas R, Shochat S, Martínez-Torrecuadrada J, Altschuh D, Meloen R, Casal JI. 2006. A fast mutagenesis procedure to recover soluble and functional scFvs containing amber stop codons from synthetic and semisynthetic antibody libraries. J. Immunol. Method. 30: 182189.
  • Barderas R, Shochat S, Timmerman P, Hollestelle MJ, Martínez-Torrecuadrada1 JL, Höppener JWM, Altschuh D, Meloen R, Casal JI. 2008a. Designing antibodies for the inhibition of gastrin activity in tumoral cell lines. Int. J. Cancer 122: 23512359.
  • Barderas R, Desmet J, Timmerman P, Meloen RH, Casal JI. 2008b. Affinity maturation of antibodies assisted by in silico modelling. Proc. Natl Acad. Sci. USA 105: 90299034.
  • Berezov A, Zhang HT, Greene MI, Murali R. 2001. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. J. Med. Chem. 44: 25652574.
  • Bès C, Briant-Longuet L, Cerruti M, De Berardinis P, Devauchelle G, Devaux C, Granier C, Chardès T. 2001. Efficient CD4 binding and immunosuppressive properties of the 13B8.2 monoclonal antibody are displayed by its CDR-H1-derived peptide CB1. FEBS Lett. 508: 6774.
  • Bès C, Briant-Longuet L, Cerutti M, Heitz F, Troadec S, Pugnière M, Roquet F, Molina F, Casset F, Bresson D, Péraldi-Roux S, Devauchelle G, Devaux C, Granier C, Chardès T. 2003. Mapping the paratope of anti-CD4 recombinant Fab 13B8.2 by combining parallel peptide synthesis and site-directed mutagenesis. J. Biol. Chem. 278: 1426514273.
  • Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van Someren N, Pounder RE, Caplin ME. 2002. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. 20: 42254231.
  • Casset F, Roux F, Mouchet P, Bès C, Chardès T, Granier C, Mani JC, Pugnière M, Laune D, Pau B, Kaczorek M, Lahana R, Rees A. 2003. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem. Biophys. Res. Commun. 307: 198205.
  • Chang H, Qin W, Li Y, Zhang J, Lin Z, Lv M, Sun Y, Feng J, Shen B. 2007. A novel human scFv fragment against TNF-alpha from de novo design method. Mol. Immunol. 44: 37893796.
  • Choulier L, Laune D, Orfanoudakis G, Wlad H, Janson J, Granier C, Altschuh D. 2001. Delineation of a linear epitope by multiple peptide synthesis and phage display. J. Immunol. Method. 249: 253264.
  • Choulier L, Rauffer-Bruyère N, Ben Khalifa M, Martin F, Vernet T, Altschuh D. 1999. Kinetic analysis of the effect on Fab binding of identical substitutions in a peptide and its parent protein. Biochemistry 38: 35303537.
  • Feng Y, Chung D, Garrard L, McEnroe G, Lim D, Scardina J, McFadden K, Guzzetta A, Lam A, Abraham J, Liu D, Endemann G. 1998. Peptides derived from the complementarity-determining regions of anti-Mac-1 antibodies block intercellular adhesion molecule-1 interaction with Mac-1. J. Biol. Chem. 273: 56255630.
  • Feng J, Li Y, Zhang W, Shen B. 2005. Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design. Immunol. Lett. 98: 311316.
  • Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. 2003. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 31: 37843788.
  • Gilliam AD, Watson SA. 2007. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin. Biol. Ther. 7: 397404.
  • Grabowska AM, Watson SA. 2007. Role of gastrin peptides in carcinogenesis. Cancer Lett. 257: 115.
  • Harper M, Lema F, Boulot G, Poljak RJ. 1987. Antigen specificity and cross-reactivity of monoclonal anti-lysozyme antibodies. Mol. Immunol. 24: 97108.
  • Heap CJ, Wang Y, Pinheiro TJ, Reading SA, Jennings KR, Dimmock NJ. 2005. Analysis of a 17-amino acid residue, virus-neutralizing microantibody. J. Gen. Virol. 86: 17911800.
  • Laune D, Molina F, Ferrières G, Mani JC, Cohen P, Simon D, Bernardi T, Piechaczyk M, Pau B, Granier C. 1997. Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins. J. Biol. Chem. 272: 3093730944.
  • Laune D, Molina F, Ferrières G, Villard S, Bès C, Rieunier F, Chardès T, Granier C. 2002. Application of the Spot method to the identification of peptides and amino acids from the antibody paratope that contribute to antigen binding. J. Immunol. Method. 267: 5370.
  • Levi M, Sallberg M, Ruden U, Herlyn D, Maruyama H, Wigzell H, Marks J, Wahren B. 1993. A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc. Natl Acad. Sci. USA 90: 43744378.
  • Levi M, Hinkula J, Wahren B. 2000. A retro-inverso miniantibody with anti-HIV activity. AIDS Res. Hum. Retroviruses 16: 5965.
  • Ma JC, Dougherty DA. 1997. The cation-π interaction. Chem. Rev. 97: 13031324.
  • Monnet C, Laune D, Laroche-Traineau J, Biard-Piechaczyk M, Briant L, Bès C, Pugnière M, Mani JC, Pau B, Cerutti M, Devauchelle G, Devaux C, Granier C, Chardès T. 1999. Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells. J. Biol. Chem. 274: 37893796.
  • Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, Wang Q, Kao G, O'Rourke DM, Greene MI, Murali R. 2000. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol. 18: 194198.
  • Perosa F, Favoino E, Caragnano MA, Dammacco F. 2004. Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope. Immunol. Lett. 95: 145153.
  • Pletneva EV, Laederach AT, Fulton DB, Kostic NM. 2001. The role of cation-pi interactions in biomolecular association. Design of peptides favoring interactions between cationic and aromatic amino acid side chains. J. Am. Chem. Soc. 123: 62326245.
  • Qin W, Feng J, Li Y, Lin Z, Shen B. 2006. Fusion protein of CDR mimetic peptide with Fc inhibit TNF-alpha induced cytotoxicity. Mol. Immunol. 43: 660666.
  • Qiu XQ, Wang H, Cai B, Wang LL, Yue ST. 2007. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat. Biotechnol. 25: 921929.
  • Rehfeld JF, Friis-Hansen L, Goetze JP, Hansen TV. 2007. The biology of cholecystokinin and gastrin peptides. Curr. Top. Med. Chem. 7: 11541165.
  • Robinson JA, Demarco S, Gombert F, Moehle K, Obrecht D. 2008. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov. Today 13: 944951.
  • Saragovi HU, Fitzpatrick D, Raktabutr A, Nakanishi H, Kahn M, Greene MI. 1991. Design and synthesis of a mimetic from an antibody complementarity-determining region. Science 253: 792795.
  • Sillerud LO, Larson RS. 2005. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr. Prot. Pept. Sci. 6: 151169.
  • Timmerman P, Beld J, Puijk WC, Meloen RH. 2005. Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces. Chem. Bio. Chem. 6: 821824.
  • Timmerman P, Barderas R, Desmet J, Altschuh D, Shochat S, Hollestelle MJ, Hoppener JW, Monasterio A, Casal JI, Meloen RH. 2009. A combinatorial approach for the design of complementarity determining regions (CDR)-derived peptidomimetics with in vitro anti-tumoral activity. J. Biol. Chem. 284: 3412634134.
  • Timmerman P, Van Dijk E, Puijk W, Schaaper W, Slootstra J, Carlisle SJ, Coley J, Eida S, Gani M, Hunt T, Perry P, Piron G, Meloen RH. 2004. Mapping of a discontinuous and highly conformational binding site on follicle stimulating hormone subunit-beta (FSH-beta) using Domain Scan and Matrix Scan technology. Mol. Divers. 8: 6177.
  • Tsumoto K, Misawa S, Ohba Y, Ueno T, Hayashi H, Kasai N, Watanabe H, Asano R, Kumagai I. 2002. Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity-determining regions (CDRs) of the monoclonal antibody. D4: tolerance of a CDR peptide to conformational changes of a target. FEBS Lett. 525: 7782.
  • Watt PM. 2006. Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat. Biotechnol. 24: 177183.
  • Williams WV, Kieber-Emmons T, Weiner DB, Rubin DH, Greene MI. 1991. Contact residues and predicted structure of the reovirus type 3-receptor interaction. J. Biol. Chem. 266: 92419250.
  • Woods AS. 2004. The mighty arginine, the stable quaternary amines, the powerful aromatics, and the aggressive phosphate: their role in the noncovalent minuet. J. Proteome Res. 3: 478484.